AzTrials
AzTrials

Diabetes MellitusNCT06988306

Lifestyle Interventions to Prevent Diabetes in U.S. Home Visiting Programs

A study testing GDM Enhanced and Meals in people with Diabetes Mellitus and Gestational Diabetes Mellitus (GDM), run by California Polytechnic State University-San Luis Obispo at 3 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The study is examining the health effects of gestational diabetes mellitus (GDM) intervention and medically tailored meals within home visiting. A large study is proposed that will include nearly a thousand pregnant or recently pregnant adults with recent GDM and who are from different regions and backgrounds. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
GDM Enhanced and Meals
Could I receive a placebo?
No, everyone receives an active treatment
How many people
978 participants
Where
3 sitesUnited States
Study dates
15 Jan 2026to 30 Apr 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Currently in home visiting
  • Pregnant or < 3 months (13 weeks) postpartum
  • Gestational Diabetes Mellitus diagnosis in most recent pregnancy (based on self-report)
  • Aged 18 years or older
  • English- or Spanish-speaking.
  • Not currently being given medically tailored meals
  • Willing to receive randomization to either group

Who cannot join

  • Pre-existing diabetes (based on self-report)

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Brooke Latzke-Davis, BS contact

805-756-5694

blatzked@calpoly.edu

United States3 sites, 3 recruiting
  • Northwestern University

    Chicago, Illinois, 60611

    Darius Tandon, PhD, 410-852-0399, dtandon@northwestern.edu

    Not yet recruiting
  • Miriam Hospital

    Providence, Rhode Island, 02906

    Rena R Wing, PhD, (401) 793-8959, rwing@brownhealth.org

    Not yet recruiting
  • California Polytechnic State University

    San Luis Obispo, California, 93401

    Suzanne Phelan, PhD, 8057562087, sphelan@calpoly.edu

    Recruiting

Other trials in United States

About this study

Official title: Randomized Controlled Trial of Lifestyle Interventions for the Prevention of Diabetes in US Home Visiting Programs

The study is examining the health effects of gestational diabetes mellitus (GDM) intervention and medically tailored meals within home visiting. A large study is proposed that will include nearly a thousand pregnant or recently pregnant adults with recent GDM and who are from different regions and backgrounds. Two treatment approaches are compared, and both are in home visiting. One treatment group is receiving enhanced lifestyle support for GDM along with meals, and the other is receiving just the enhanced lifestyle support. The study will examine whether these interventions help reduce diabetes and pre-diabetes through 12 months postpartum, as well as other health factors like weight and blood pressure.

Read the detailed description

Gestational diabetes mellitus (GDM) is rapidly rising in prevalence and has been linked with several short and long-term adverse maternal health outcomes, including type 2 diabetes (T2DM) and cardiovascular disease. The postpartum year is a time of heightened risk, and 32-46% of people with GDM develop type 2 diabetes (T2DM) or Pre-Diabetes (PreDM) during the postpartum year. To prevent maternal diabetes, US guidelines recommend behavioral counseling to promote healthy eating, activity, and weight, but dissemination channels have been lacking. Evidence-based home visiting programs, with their well-established infrastructure in every state and focus on maternal and child health, are a promising platform through which the recommended behavioral interventions could reach people with GDM and reduce health disparities. Effective GDM intervention within home visiting needs to be potent, build on existing content, and remain brief, so as not to displace other evidence-based content. Integrating referral to medically tailored meals (MtMs) is a Food is Medicine strategy that may prevent and mitigate maternal diabetes in home visiting. Access to MtMs has been expanding rapidly in the US, with 10 states currently having and 5 states pending Medicaid Service waivers that offer coverage for MtMs. Systematic reviews have found that providing MtMs allows patients to experience significantly better glucose and weight management, improved food insecurity and dietary quality, and greater treatment satisfaction. MtMs also benefit health systems, insurers, and governments through reduced costs and fewer hospitalizations and emergency department visits. However, national calls and systematic reviews have identified a major evidence gap and the need for adequately powered effectiveness trials to determine whether MtMs are effective in treating and preventing maternal diabetes. For MtMs to continue as a treatment approach for GDM, compelling evidence is needed that they work and for whom and in what context. The primary aim of this study is to evaluate the 12-month incidence T2DM/PreDM in people with GDM who receive GDM Enhanced + Meals vs. GDM Enhanced Only within home visiting. A robust implementation process evaluation will inform ensure successful sustainment and reach for diverse pregnant and postpartum people with GDM. A Hybrid Type 1 effectiveness-implementation trial is proposed. The study will recruit 978 perinatal, English or Spanish-speaking adults nationwide from three clinical centers serving the West, Midwest/South, and East regions. Home visiting clients (35% Black; 40% Hispanic) with recent GDM diagnosis and will be randomized within site and home visiting agency to one of two treatment arms: GDM enhanced lifestyle intervention plus MtMs (GDM Enhanced + Meals) or GDM Enhanced Only. The primary study aim is to evaluate the 12-month incidence of T2DM/PreDM. Secondary aims will examine treatment group differences in health factors (weight, blood pressure) and client-centered outcomes (diet quality, physical activity, home food environment, food security, quality of life, treatment satisfaction, self-efficacy, mood) at 3, 6, and 12 months postpartum. Key moderators (Black/White race, Hispanic/Non-Hispanic ethnicity, food security), and mediators (changes in weight, dietary quality, physical activity, and the home food environment) will be identified. The RE-AIM framework will guide an implementation process evaluation to plan for successful delivery and sustainment of the interventions. Findings from this from large scale, adequately powered trial of MtMs for maternal health will fill a major gap in the literature. If the MTM approach is found effective, there will be strong justification to bolster access (at state level) and referrals (within home visiting) to MtMs. Findings will inform tailored strategies to ensure successful sustainment in home visiting and reach for diverse pregnant and postpartum people with GDM.

Being tested
GDM Enhanced, Meals
Keywords
medically tailored meals, gestational diabetes, food is medicine, home visiting
Medical subject headings
Diabetes Mellitus, Diabetes, Gestational

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GDM EnhancedBehavioural

    The GDM Enhanced intervention is comprised of HV-delivered, evidence-based modules (10-20 minutes) with facilitator guides. The content prioritizes management and prevention of diabetes through healthy eating, physical activity, and stigma-informed weight management strategies.

  • MealsBehavioural

    The Meal intervention includes medically tailored meals being provided to participants starting after randomization and tailored to their individual dietary preferences and cultural considerations.

Study groups in NCT06988306
Study groupRoleWhat they receive
Usual Home Visiting plus GDM EnhancedActive comparatorThis group receives usual home visitation plus GDM Enhanced intervention.
Receives: Behavioral: GDM Enhanced
Usual HV + GDM Enhanced + MealsExperimentalThis group will receive usual home visitation plus GDM Enhanced plus medically tailored meals.
Receives: Behavioral: GDM Enhanced; Behavioral: Meals

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diabetes/Pre-Diabetes

    The Primary Outcome Measure in this study is a categorical outcome of glucose tolerance (i.e., healthy glucose tolerance vs. type 2 diabetes/pre-diabetes) at 12 months postpartum. The test will be conducted at CLIA-certified lab. A 2-hour oral glucose tolerance test (OGTT) will characterize people into one of two categories: 1) healthy glucose tolerance; or 2) type 2 diabetes (2-hour post 75g load glucose level of 200 mg/dL or greater) or pre-diabetes (a 2-hour post 75g load glucose level of 140 to 199 mg/d).

    Measured: From enrollment to 12 months postpartum

Secondary outcomes (14)
  1. HbA1c concentration

    HbA1c will be measured utilizing an at-home test kit (finger-stick, whole-blood test)

    Measured: From enrollment to 3, 6, and 12 months postpartum

  2. Systolic blood pressure

    Systolic blood pressure will be self-measured in the home with trained research assistants guiding the assessment

    Measured: From enrollment to 3, 6, and 12 months postpartum

  3. Diastolic blood pressure

    Diastolic blood pressure will be self-measured in the home with trained research assistants guiding the assessment

    Measured: From enrollment to 3, 6, and 12 months postpartum

  4. Body weight

    Body weight is obtained using remote scales provided to participants.

    Measured: From enrollment to 3, 6, and 12 months postpartum

  5. Child zBMI

    Remote, guided parent measurements of child weight and length will be used to calculate the child's body mass index z-score (zBMI), along with parent-reported infant sex.

    Measured: From 3 months to 6 and 12 months

  6. Diet quality

    The Automated Self-Administered (ASA) 24-hour Recall of the National Cancer Institute will be used by trained staff to obtain an interview-based assessment of dietary quality. Healthy Eating Index (HEI) scores will be calculated by linking ASA24 output to the HEI scoring algorithm, which evaluates diet quality based on alignment with the Dietary Guidelines for Americans.Scores range from 0 to 100.

    Measured: From enrollment to 3, 6, and 12 months postpartum

  7. Metabolic equivalent task minutes per week of moderate-to-vigorous physical activity

    The International Physical Activity Questionnaire will be used to measure metabolic equivalent task (MET)-minutes per week of moderate-to-vigorous physical activity. Scores range from 0 to >10,000 MET-minutes/week, with higher scores indicating greater physical activity, which is considered a better outcome.

    Measured: From enrollment to 3, 6, and 12 months postpartum

  8. Home Food Environment

    The home food environment checklist will be used to measure number of healthy foods in the home. Higher scores indicate a greater number of healthy foods present.

    Measured: From enrollment to 3, 6, and 12 months postpartum

  9. Food Security

    The U.S. Household food security survey will be used to measure a categorical classification or high food security, marginal food security, low food security, and very low food security

    Measured: From enrollment to 3, 6, and 12 months postpartum

  10. Global Physical Health

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health 10-item scale will be used to assess Global Physical Health (GPH). Raw scores are converted to T-scores, standardized to the U.S. general population (mean = 50, SD = 10). T-scores typically range from 20 to 80, with higher scores indicating better health.

    Measured: From enrollment to 3, 6, and 12 months postpartum

  11. Global Mental Health

    The Patient-Reported Outcomes Measurement Information System Global Health 10-item scale will be used to assess Global Mental Health. Raw scores are converted to T-scores, standardized to the U.S. general population (mean = 50, SD = 10). T-scores typically range from 20 to 80, with higher scores indicating better health.

    Measured: From enrollment to 3, 6, and 12 months postpartum

  12. Nutrition Self-Efficacy

    The Nutrition Self-Efficacy Scale will be used to assess participants' confidence in their ability to engage in healthy eating, yielding a continuous self-efficacy score. Each item is rated on a 5-point Likert scale from 1 (not at all confident) to 5 (very confident), resulting in a total score range of 10 to 50. Higher scores reflect greater self-efficacy for healthy eating behaviors

    Measured: From enrollment to 3, 6, and 12 months postpartum

  13. Center for Epidemiologic Studies Depression Scale

    The Center for Epidemiologic Studies Depression Scale - 10-item version (CES-D-10) will be used to assess depressive symptoms. Each item is rated on a 4-point Likert scale from 0 (rarely or none of the time) to 3 (most or all of the time), yielding a total score range of 0 to 30. Higher scores indicate greater depressive symptomatology.

    Measured: From enrollment to 3, 6, and 12 months postpartum

  14. Barriers to Healthy Eating

    Barriers to Healthy Eating Questionnaire is 14-items and assesses perceived barriers to healthy eating. The total score is calculated by summing all 14 items. Total scores range from 0 to 14, with higher scores reflecting greater overall perceived barriers to following a healthy eating pattern.

    Measured: From enrollment to 3, 6, and 12 months postpartum

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 May 2025
  2. Study start15 Jan 2026
  3. Primary completion30 Apr 2030 (estimated)
  4. Study completion30 Apr 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Care provider, Outcomes assessor
Enrolment
978 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06988306
Sponsor's protocol ID
2025-056
Other IDs
MMM-2024C1-37760
Status last verified
Mar 2026
First submitted
6 Apr 2025
Last updated
5 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: We will share de-identified individual participant data related to primary and secondary outcomes. These data may include measures of diabetes, physical activity, diet quality, and other health indicators.

Questions about this trial

What is this clinical trial studying?

A study testing GDM Enhanced and Meals in people with Diabetes Mellitus and Gestational Diabetes Mellitus (GDM), run by California Polytechnic State University-San Luis Obispo at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Brooke Latzke-Davis, BS (805-756-5694, blatzked@calpoly.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diabetes/Pre-Diabetes (time frame: From enrollment to 12 months postpartum). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in